Qiagen NV reported earnings results for the first quarter ended March 31, 2013. Net income attributable to owners of the company amounted to $20.0 million in the first quarter of 2013 compared to $28.6 million in the year-ago period. Diluted EPS was $0.08 compared to $0.12 in the year-ago period and due mainly to higher amortization and business integration expenses compared to the same period in 2012. Operating income declined 20% to $29.1 million in the first quarter of 2013 compared to $36.5 million in the first quarter of 2012. Adjusted operating income, which excludes items such as restructuring and acquisition-related costs, share-based compensation and amortization of intangible assets, was down 2% to $78.4 million from $80.3 million in the first quarter of 2012. Adjusted net income attributable to owners of the company was largely unchanged at $54.7 million compared to $54.8 million in the 2012 quarter, and adjusted diluted EPS was also unchanged at $0.23 in the first quarter of 2013 compared to the year-ago period. Net cash provided by operating activities amounted to $45.9 million at the end of the first quarter of 2013, up from $11.1 million at the end of the same period of 2012, with free cash flow significantly improving to $30.1 million from negative free cash flow of $7.7 million. Net Sales were $303.6 million against $296.4 million a year ago. Net sales grew 3% CER at constant exchange rates in the first quarter of 2013, led by the Molecular Diagnostics (11% CER) and Applied Testing (5% CER) customer classes, more than offsetting lower contributions in Pharma (4% CER) and Academia (4% CER). Net debt rose to $405 million from $342 million. The company continues to expect to deliver improved results in 2013, having updated targets for adjusted net sales and adjusted diluted earnings per share for the full year to incorporate the impact of new developments during the first quarter. The company currently expects reduced government funding, including the implementation of sequestration in the U.S., to have an adverse impact of at least 1% point on adjusted net sales growth in 2013, while the acquisition of Ingenuity is expected to provide adjusted net sales of approximately $15 million in 2013. As a result of these factors, The company expects adjusted net sales to grow approximately 5% CER in 2013. The company also now expects adjusted diluted EPS of approximately $1.13 for full-year 2013, which includes dilution of $0.03 per share from the Ingenuity acquisition. The adjusted tax rate is expected to be around 20% to 22%. For the second quarter of 2013, the company expects adjusted net sales to grow approximately 1% to 2% CER and for adjusted diluted EPS of approximately $0.25, and for faster adjusted net sales and adjusted earnings growth rates in the second half of the year. The adjusted tax rate is expected to be about 23%.

Qiagen NV announced proposals for changes in the membership of the Supervisory Board that will be put forward for approval by shareholders at the next Annual General Meeting scheduled for June 26, 2013. The proposals for the composition of the Supervisory Board, who are elected to one-year terms, were made by the Selection and Appointment Committee and recommended for shareholder approval by a Joint Meeting of the Supervisory Board and the Managing Board. Two new members have been proposed for election to the Supervisory Board: Stéphane Bancel, 40, is President and Founding CEO of Moderna Therapeutics Inc., a start-up biotechnology company based in Cambridge, Massachusetts, that is advancing multiple drug development programs involving messenger RNA therapeutics. Lawrence A. Rosen, 55, is a member of the Board of Management and Chief Financial Officer of Deutsche Post DHL. In this position, which he has held since September 2009, Rosen is in charge of Controlling, Corporate Accounting and Reporting, Investor Relations, Corporate Finance, Corporate Internal Audit and Security, Taxes, as well as the Group's Global Business Services. Two members of the Supervisory Board - Mr. Erik Hornnaess and Mr. Heino von Prondzynski - have decided not to stand for re-election. Mr. Hornnaess has been a member of the Supervisory Board since 1998 and currently serves as Deputy Chairman of the Supervisory Board, Chairman of the Compensation Committee, Member of the Audit Committee and the Selection and Appointment Committee. Mr. von Prondzynski has been a member of the Supervisory Board since 2007 and also served as a Member of the Audit Committee.

Qiagen NV Presents at Merrill Lynch 2013 Health Care Conference, May-15-2013 10:40 AM. Venue: Encore at Wynn, 3121 Las Vegas Blvd South, Las Vegas, Nevada, United States. Speakers: Roland Sackers, Chief Financial Officer, Managing Director and Member of Management Board.